

Old and new lines drive growth

DT's CMD outlined strategy for the next five years. SBU might be in some ways the most mature application area, but its volume recovery will be crucial to earnings in the short-term.

All product application areas have various growth drivers

DT aims to grow at a 10% CAGR, vs the ca. 3% estimated market growth, over the next five years so that the 2030 top line would be some EUR 170m; the EUR 65m implied growth would stem in relatively even proportions from SBU, MBU and IBU, although it seems DT expects IBU to grow the most in relative terms as there's big potential within TFT while the company's software efforts should also help the area more due to the nature of its customer base and volumes. IBU demand also benefits from the fact that the detectors in such applications wear out a lot faster than the ones used within MBU and SBU. MBU too should help TFT volumes, driven by both dental and surgical applications. DT looks to grow its customer wallet share particularly in SBU, driven by mature and competitive CT products for aviation and cargo, however TFT doesn't seem to play a big role there.

Targets imply around EUR 25m in EBITA for the year 2030


DT didn't make changes to its medium-term financial targets; in our view the 15% EBITA margin target is realistic especially if the targeted growth materializes (due to operational leverage). DT is positioned as an OEM product enabler, so it doesn't need to use huge amounts of money on relatively mature technologies like CT, yet R&D as a share of revenue might remain in the double-digits due to emerging technologies such as photon counting as well as the ambition to strengthen TFT and software capabilities. SBU is perhaps the most mature area from a technology perspective, while MBU and IBU are likely to see more changes.

We make no estimate changes at this point

China stays a key location for DT in terms of demand and production, yet the Oulu manufacturing share might grow to 15% next year. India is another opening but will not alter DT's China exposure much very soon. DT has indicated it will resume double-digit growth early next year, and in our view it's reasonable to expect a similar rate for FY'26 as SBU volumes recover while MBU and IBU have many drivers. DT is valued 15x EV/EBIT on our FY'25 estimates, but the multiple should decline to 9x next year since earnings are to recover with volumes. We retain our EUR 11.5 TP and ACCUMULATE rating.

Rating

Accumulate



Share price, EUR (Last trading day's closing price)	10.80
Target price, EUR	11.5
Latest change in recommendation	16-Apr-25
Latest report on company	31-Oct-25
Research paid by issuer:	YES
No. of shares outstanding, '000's	14 656
No. of shares fully diluted, '000's	14 656
Market cap, EURm	158
Free float, %	—
Exchange rate	—
Reuters code	DETEC.HE
Bloomberg code	DETEC FH
Average daily volume, EURm	0.1
Next interim report	05-Feb-26
Web site	deetee.com/investors/
Analyst	Joonas Ilvonen
E-mail	joonas.ilvonen@evli.com
Telephone	+358 44 430 9071

BUY ACCUMULATE REDUCE SELL

KEY FIGURES

	Sales EURm	EBIT EURm	EBIT %	FCF EURm	EPS EUR	P/E (x)	EV/Sales (x)	EV/EBIT (x)	FCF yield %	DPS EUR
2023	103.8	8.2	7.9%	21.1	0.38	29.3	1.8	23.1	10.5%	0.23
2024	107.5	13.8	12.8%	16.9	0.76	20.2	1.8	14.3	7.5%	0.50
2025E	101.6	9.2	9.0%	6.1	0.45	23.7	1.3	14.3	3.9%	0.30
2026E	111.4	15.3	13.7%	6.4	0.77	14.0	1.2	8.5	4.1%	0.51
2027E	121.4	17.7	14.6%	9.4	0.98	11.0	1.1	7.2	5.9%	0.65
Market cap, EURm	158	Gearing 2025E, %		-33.1 %		CAGR EPS 2024-27, %		8.9 %		
Net debt 2025E, EURm	-27	Price/book 2025E		1.9		CAGR Sales 2024-27, %		4.1 %		
Enterprise value, EURm	132	Dividend yield 2025E, %		2.8 %		ROE 2025E, %		8.1 %		
Total assets 2025E, EURm	102	Tax rate 2025E, %		18.4 %		ROCE 2025E, %		10.9 %		
Goodwill 2025E, EURm	0	Equity ratio 2025E, %		79.6 %		PEG, P/E 25/CAGR		0.7		

All the important disclosures can be found on the last pages of this report.

Estimates and peer valuation

Estimates	2022	2023	Q1'24	Q2'24	Q3'24	Q4'24	2024	Q1'25	Q2'25	Q3'25	Q4'25E	2025E
Net sales	98.6	103.8	22.7	26.1	27.1	31.6	107.5	22.2	24.4	24.7	30.2	101.4
Medical	48.1	48.4	9.5	9.3	10.9	12.5	42.2	10.8	10.6	10.4	12.8	44.5
Security	34.4	39.3	9.6	11.5	11.3	13.9	46.3	7.7	8.2	9.8	12.1	37.8
Industrial	16.1	16.2	3.6	5.3	4.9	5.2	19.0	3.8	5.6	4.5	5.3	19.1
Adj. EBITA	6.1	9.7	2.3	3.3	4.2	5.2	14.9	1.4	1.7	2.8	4.5	10.5
<i>Net sales growth—%</i>	<i>10%</i>	<i>5%</i>	<i>0%</i>	<i>3%</i>	<i>11%</i>	<i>1%</i>	<i>4%</i>	<i>−2%</i>	<i>−7%</i>	<i>−9%</i>	<i>−5%</i>	<i>−6%</i>
<i>Medical</i>	<i>−2%</i>	<i>0%</i>	<i>−21%</i>	<i>−25%</i>	<i>1%</i>	<i>−5%</i>	<i>−13%</i>	<i>14%</i>	<i>14%</i>	<i>−5%</i>	<i>2%</i>	<i>6%</i>
<i>Security</i>	<i>23%</i>	<i>14%</i>	<i>32%</i>	<i>27%</i>	<i>16%</i>	<i>5%</i>	<i>18%</i>	<i>−20%</i>	<i>−28%</i>	<i>−13%</i>	<i>−13%</i>	<i>−18%</i>
<i>Industrial</i>	<i>26%</i>	<i>1%</i>	<i>5%</i>	<i>43%</i>	<i>23%</i>	<i>4%</i>	<i>18%</i>	<i>4%</i>	<i>4%</i>	<i>−8%</i>	<i>2%</i>	<i>1%</i>
<i>Adj. EBITA margin</i>	<i>6.2%</i>	<i>9.3%</i>	<i>10%</i>	<i>13%</i>	<i>15%</i>	<i>16%</i>	<i>13.9%</i>	<i>6%</i>	<i>7%</i>	<i>12%</i>	<i>15%</i>	<i>10.3%</i>

DETECTION TECHNOLOGY PEER GROUP	MCAP MEUR	EV/EBITDA			EV/EBIT			P/E		
		25	26	27	25	26	27	25	26	27
Hamamatsu Photonics	2541	9.5x	9.1x	8.4x	24.6x	19.0x	15.8x	31.2x	26.7x	22.5x
OSI Systems	3815	16.7x	15.5x	14.1x	20.3x	18.9x	17.4x	26.4x	24.1x	21.8x
Varex Imaging	404	6.4x	6.0x			9.4x		15.8x	13.2x	
ams—OSRAM	874	4.3x	3.8x	3.4x	8.4x	7.2x	6.1x	40.4x	7.9x	4.7x
Analog Devices	97337	24.0x	20.6x	18.1x	25.1x	21.0x	18.8x	28.5x	23.7x	20.6x
Keysight Tech	25712	19.3x	17.3x		21.2x	18.8x		24.1x	21.7x	19.4x
Comet Holding	1550	26.4x	15.4x	11.0x	45.1x	20.8x	13.7x	58.0x	26.2x	17.1x
Texas Instruments	121250	18.8x	16.3x	14.3x	24.9x	22.2x	18.4x	28.2x	25.4x	21.0x
Oxford Instruments	1278	13.2x	12.4x	11.2x	15.3x	14.3x	12.9x	19.9x	18.3x	16.3x
Trimble	15430	18.7x	17.4x	15.7x	19.8x	18.1x	16.8x	24.3x	21.8x	19.1x
Hexagon	26471	15.4x	13.5x	13.1x	20.8x	19.5x	17.6x	24.4x	22.3x	19.7x
Konica Minolta	1695	7.8x	5.9x	5.9x	35.5x	13.5x	12.8x	50.8x	11.6x	10.5x
iRay Technology Company	2640	24.5x	18.2x	14.4x	34.6x	27.2x	21.6x	32.2x	25.6x	20.7x
Vieworks	100	7.0x	6.0x	5.2x	9.8x	8.1x	6.8x	11.4x	8.5x	7.3x
Peer Group Average	21507	15.1x	12.7x	11.2x	23.5x	17.0x	14.9x	29.7x	19.8x	17.0x
Peer Group Median	2590	16.0x	14.4x	12.1x	21.2x	18.9x	16.3x	27.3x	22.1x	19.4x
Detection Technology (Evli est.)	158	10.4x	6.7x	5.9x	14.3x	8.4x	7.2x	23.7x	14.0x	11.0x
<i>Detection Technology prem./disc. to peer median</i>		<i>−35 %</i>	<i>−53 %</i>	<i>−51 %</i>	<i>−33 %</i>	<i>−55 %</i>	<i>−56 %</i>	<i>−13 %</i>	<i>−37 %</i>	<i>−43 %</i>

DETECTION TECHNOLOGY PEER GROUP	Sales 25	Sales gr.			EBIT—%			Div. yield		
		25	26	27	25	26	27	25	26	27
Hamamatsu Photonics	1209	−16.0%	5.9%	5.5%	8.1 %	9.8 %	11.2 %	2.5 %	2.6 %	2.8 %
OSI Systems	1531	30.0%	6.5%	5.5%	14.3 %	14.4 %	14.9 %		0.0 %	
Varex Imaging	725	−12.2%	3.4%		−0.6 %	8.8 %				
ams—OSRAM	3326	−31.0%	4.4%	5.4%	8.9 %	9.9 %	11.2 %	0.0 %	0.0 %	0.0 %
Analog Devices	9659	−17.3%	12.5%	8.2%	42.4 %	45.0 %	46.4 %	1.7 %	1.9 %	2.0 %
Keysight Tech	4672	−10.7%	9.3%	8.2%	25.5 %	26.3 %		0.0 %	0.0 %	
Comet Holding	505	−14.0%	14.4%	17.0%	6.8 %	12.9 %	16.7 %	0.7 %	1.3 %	1.9 %
Texas Instruments	15267	−16.9%	7.9%	10.4%	34.0 %	35.5 %	38.7 %	3.5 %	3.7 %	3.8 %
Oxford Instruments	508	−2.0%	−1.1%	5.2%	17.0 %	18.2 %	19.1 %	1.2 %	1.2 %	1.3 %
Trimble	3074	−10.3%	7.4%	8.5%	27.3 %	27.8 %	27.5 %			
Hexagon	5457	5.7%	2.5%	6.3%	26.7 %	27.7 %	28.9 %	1.3 %	1.4 %	1.6 %
Konica Minolta	6105	−19.9%	−4.6%	0.0%	1.7 %	4.5 %	4.7 %	1.2 %	1.9 %	2.2 %
iRay Technology Company	265	25.1%	37.8%	23.5%	29.1 %	26.9 %	27.4 %	0.3 %	0.4 %	0.5 %
Vieworks	139	−17.4%	7.8%	8.8%	8.6 %	9.7 %	10.6 %	3.2 %	3.4 %	3.7 %
Peer Group Average	3746	−7.6%	8.2%	8.7%	17.8 %	19.8 %	21.4 %	1.4 %	1.5 %	2.0 %
Peer Group Median	2303	−13.1%	7.0%	8.2%	15.6 %	16.3 %	17.9 %	1.2 %	1.3 %	1.9 %
Detection Technology (Evli est.)	102	−5.5%	9.6%	9.0%	9.0 %	13.7 %	14.6 %	2.8 %	4.7 %	6.0 %

Source FactSet, Evli Research

VALUATION RESULTS	BASE CASE DETAILS	VALUATION ASSUMPTIONS	ASSUMPTIONS FOR WACC
Current share price	10.80 PV of Free Cash Flow	88 Long-term growth, %	2.6 % Risk-free interest rate, %
DCF share value	18.09 PV of Horizon value	156 WACC, %	8.5 % Market risk premium, %
Share price potential, %	67.5 % Unconsolidated equity	0 Spread, %	0.0 % Debt risk premium %
Maximum value	18.1 Marketable securities	28 Minimum WACC, %	8.5 % Equity beta coefficient
Minimum value	18.1 Debt – dividend	–7 Maximum WACC, %	8.5 % Target debt ratio, %
Horizon value, %	63.9 % Value of stock	265 No. of shares, Mn	14.7 Effective tax rate, %

DCF valuation, EURm	2024	2025E	2026E	2027E	2028E	2029E	2030E	2031E	2032E	2033E	2034E	TERMINAL
Net sales	108	102	111	121	129	136	145	149	153	158	162	166
Sales growth (%)	3.6%	–5.5%	9.7%	9.0%	6.0%	6.0%	6.0%	3.0%	3.0%	3.0%	2.6%	2.6%
Operating income (EBIT)	14	9	15	18	20	21	22	23	24	24	25	26
Operating income margin %	12.8%	9.0%	13.7%	14.6%	15.5%	15.5%	15.5%	15.5%	15.5%	15.5%	15.5%	15.5%
+ Depreciation+amort.	3	3	4	4	4	4	5	5	5	5	5	
EBITDA	17	12	20	21	24	26	27	28	29	30	31	
– Paid taxes	–2	–2	–4	–3	–4	–4	–4	–4	–4	–5	–5	
– Change in NWC	5	–2	–4	–4	–3	–3	–3	–2	–2	–2	–2	
NWC / Sales, %	35.9%	39.5%	39.6%	39.7%	39.8%	39.9%	39.9%	40.0%	40.0%	40.0%	40.0%	
+ Change in other liabs												
– Operative CAPEX	–2	–2	–5	–5	–5	–5	–5	–5	–5	–5	–5	
opCAPEX / Sales, %	2.1%	1.7%	4.8%	3.8%	3.7%	3.7%	3.7%	3.4%	3.4%	3.4%	3.3%	
– Acquisitions												
+ Divestments												
– Other items												
= FCFF	17	7	7	9	13	14	14	17	17	18	19	328
= Discounted FCFF		7	6	8	10	10	9	10	10	9	9	156
= DFCF min WACC		7	6	8	10	10	9	10	10	9	9	156
= DFCF max WACC		7	6	8	10	10	9	10	10	9	9	156

Sensitivity analysis, EUR

		Terminal WACC				
		6.48 %	7.48 %	8.48 %	9.48 %	10.48 %
Terminal EBIT–%	13.50 %	23.86	19.28	16.25	14.10	12.50
	14.50 %	25.51	20.48	17.17	14.83	13.08
	15.50 %	27.16	21.69	18.09	15.55	13.66
	16.50 %	28.81	22.89	19.01	16.27	14.24
	17.50 %	30.45	24.10	19.93	16.99	14.82

INTERIM FIGURES

EVLI ESTIMATES, EURm	2024Q1	2024Q2	2024Q3	2024Q4	2024	2025Q1	2025Q2	2025Q3	2025Q4E	2025E	2026E	2027E
Net sales	22.7	26.1	27.1	31.6	107.5	22.2	24.4	24.8	30.2	101.6	111.4	121.4
EBITDA	2.9	3.8	4.8	5.5	17.0	1.8	2.1	3.5	5.2	11.9	19.7	21.4
EBITDA margin (%)	12.8%	14.4%	17.7%	17.5%	15.8%	8.1%	8.6%	14.1%	17.1%	11.7%	17.7%	17.6%
EBIT	2.0	3.0	3.9	4.9	13.8	1.1	1.4	2.4	4.3	9.2	15.3	17.7
EBIT margin (%)	8.8%	11.5%	14.4%	15.4%	12.8%	5.0%	5.7%	9.7%	14.1%	9.0%	13.7%	14.6%
Net financial items	-0.2	-0.2	0.0	0.0	-0.4	-0.2	-0.6	-0.1	-0.1	-1.0	-0.4	-0.1
Pre-tax profit	1.9	2.8	3.9	4.8	13.3	0.9	0.8	2.3	4.2	8.2	14.9	17.6
Tax	-0.4	-0.4	-0.6	-0.8	-2.2	-0.2	0.2	-0.7	-0.8	-1.5	-3.6	-3.3
Tax rate (%)	21.6%	13.0%	16.5%	17.3%	16.8%	22.2%	-23.5%	29.4%	19.2%	18.4%	23.3%	18.0%
Net profit	1.5	2.4	3.2	4.0	11.1	0.7	1.0	1.6	3.4	6.7	11.3	14.3
EPS	0.10	0.16	0.22	0.27	0.76	0.05	0.07	0.11	0.23	0.45	0.77	0.98
EPS adj. (diluted)	0.10	0.16	0.22	0.27	0.76	0.05	0.07	0.11	0.23	0.45	0.77	0.98
Dividend per share					0.50					0.30	0.51	0.65
SALES, EURm	2024Q1	2024Q2	2024Q3	2024Q4	2024	2025Q1	2025Q2	2025Q3	2025Q4E	2025E	2026E	2027E
MBU	9.5	9.3	10.9	12.5	42.2	10.8	10.6	10.4	12.8	44.6	47.9	51.2
SBU	9.6	11.5	11.2	14.0	46.3	7.7	8.2	9.9	12.1	37.9	42.8	48.0
IBU	3.6	5.3	5.0	5.1	19.0	3.8	5.6	4.5	5.3	19.1	20.7	22.2
Total	22.7	26.1	27.1	31.6	107.5	22.2	24.4	24.8	30.2	101.6	111.4	121.4
SALES GROWTH, Y/Y %	2024Q1	2024Q2	2024Q3	2024Q4	2024	2025Q1	2025Q2	2025Q3	2025Q4E	2025E	2026E	2027E
MBU	-21.0%	-25.3%	0.5%	-4.6%	-12.8%	13.7%	13.9%	-4.5%	2.0%	5.6%	7.5%	7.0%
SBU	31.5%	26.7%	15.3%	6.1%	17.8%	-20.0%	-28.2%	-12.0%	-13.6%	-18.2%	13.0%	12.0%
IBU	5.2%	42.6%	26.1%	2.0%	18.0%	4.2%	4.3%	-9.6%	4.5%	0.7%	8.0%	7.5%
Total	-0.2%	3.5%	10.5%	1.0%	3.6%	-2.0%	-6.6%	-8.6%	-4.5%	-6.5%	9.7%	9.0%
EBIT, EURm	2024Q1	2024Q2	2024Q3	2024Q4	2024	2025Q1	2025Q2	2025Q3	2025Q4E	2025E	2026E	2027E
Group	2.0	3.0	3.9	4.9	13.8	1.1	1.4	2.4	4.3	9.2	15.3	17.7
Total	2.0	3.0	3.9	4.9	13.8	1.1	1.4	2.4	4.3	9.2	15.3	17.7
EBIT margin %	2024Q1	2024Q2	2024Q3	2024Q4	2024	2025Q1	2025Q2	2025Q3	2025Q4E	2025E	2026E	2027E
Group	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Total	8.8%	11.5%	14.4%	15.4%	12.8%	5.0%	5.7%	9.7%	14.1%	9.0%	13.7%	14.6%

INCOME STATEMENT, EURm	2020	2021	2022	2023	2024	2025E	2026E	2027E
Sales	81.6	89.8	98.6	103.8	107.5	101.6	111.4	121.4
<i>Sales growth (%)</i>	-20.4%	10.1%	9.8%	5.3%	3.6%	-5.5%	9.7%	9.0%
EBITDA	11.9	13.9	9.1	11.8	17.0	11.9	19.7	21.4
<i>EBITDA margin (%)</i>	14.6%	15.4%	9.2%	11.3%	15.8%	11.7%	17.7%	17.6%
Depreciation	-3.2	-3.3	-3.3	-3.6	-3.2	-2.7	-3.9	-3.1
EBITA	8.7	10.6	5.8	8.2	13.8	9.2	15.9	18.3
Goodwill amortization / writedown							-0.6	-0.6
EBIT	8.7	10.6	5.8	8.2	13.8	9.2	15.3	17.7
<i>EBIT margin (%)</i>	10.7%	11.8%	5.9%	7.9%	12.8%	9.0%	13.7%	14.6%
Reported EBIT	8.7	10.6	5.8	8.2	13.8	9.2	15.3	17.7
<i>EBIT margin (reported) (%)</i>	10.7%	11.8%	5.9%	7.9%	12.8%	9.0%	13.7%	14.6%
Net financials	-0.6	0.8	-0.2	-0.9	-0.4	-1.0	-0.4	-0.1
Pre-tax profit	8.1	11.4	5.6	7.3	13.3	8.2	14.9	17.6
Taxes	-1.4	-2.1	-0.4	-1.8	-2.2	-1.5	-3.6	-3.3
Minority shares								
Net profit	6.7	9.3	5.1	5.5	11.1	6.7	11.3	14.3
Cash NRIs								
Non-cash NRIs								
BALANCE SHEET, EURm								
Assets								
Fixed assets	10	9	7	17	16	15	16	18
Goodwill							-1	-1
Right of use assets								
Inventory	16	22	25	24	23	23	26	28
Receivables	25	31	36	35	33	34	37	40
Liquid funds	25	30	24	19	28	31	32	31
Total assets	76	92	91	95	100	102	110	115
Liabilities								
Shareholders' equity	58	74	73	73	82	82	89	95
Minority interest				0	0	0	0	0
Convertibles								
Lease liabilities								
Deferred taxes								
Interest bearing debt	6	2	3	6		4	3	
Non-interest bearing current liabilities	11	15	14	14	16	15	17	18
Other interest-free debt	1	1	1	1	1	1	1	1
Total liabilities	76	92	91	95	100	102	110	115
CASH FLOW, EURm								
+ EBITDA	12	14	9	12	17	12	20	21
- Net financial items	-1	3	-6	-1	0	-1	0	0
- Taxes	-3	-1	-2	-2	-2	-2	-4	-3
- Increase in Net Working Capital	0	-6	-9	2	5	-2	-4	-4
+/- Other	-1	-3	7					
= Cash flow from operations	8	7	0	11	19	8	12	14
- Capex	-3	-1	-2	-2	-2	-2	-5	-5
- Acquisitions				12				
+ Divestments								
= Free cash flow	4	6	-2	21	17	6	6	9
+/- New issues/buybacks	-1	10	-1	-2	2			
- Paid dividend	4	5	3	3	7	4	7	9
+/- Other	1	-7	2	-20	-6	4	-1	-3
Change in cash	-1	5	-6	-5	9	2	2	-1

KEY FIGURES	2021	2022	2023	2024	2025E	2026E	2027E
M–cap	429	248	202	224	158	158	158
Net debt (excl. convertibles)	–28	–21	–13	–28	–27	–29	–31
Enterprise value	402	227	189	196	132	129	128
Sales	90	99	104	108	102	111	121
EBITDA	14	9	12	17	12	20	21
EBIT	11	6	8	14	9	15	18
Pre–tax	11	6	7	13	8	15	18
Earnings	9	5	5	11	7	11	14
Equity book value (excl. minorities)	74	73	73	82	82	89	95

Valuation multiple	2021	2022	2023	2024	2025E	2026E	2027E
EV/Sales	4.5	2.3	1.8	1.8	1.3	1.2	1.1
EV/EBITDA	29.0	25.0	16.1	11.6	11.1	6.6	6.0
EV/EBITA	38.0	39.2	23.1	14.3	14.3	8.2	7.0
EV/EBIT	38.0	39.2	23.1	14.3	14.3	8.5	7.2
EV/OCF	56.4	–772.5	17.7	10.3	16.8	11.0	9.2
EV/FCF	78.5	–132.7	8.7	11.4	18.9	19.3	13.5
P/FCFR	74.5	–128.9	9.6	13.3	25.8	24.7	16.9
P/E	46.4	45.3	29.3	20.2	23.7	14.0	11.0
P/BV	5.8	3.4	2.8	2.7	1.9	1.8	1.7
Target EV/EBITDA					11.9	7.1	6.4
Target EV/EBIT					15.4	9.1	7.8
Target EV/FCFF					23.1	21.8	14.7
Target P/BV					2.1	1.9	1.8
Target P/E, diluted	44.4	49.2	36.8	23.4	25.3	14.9	11.8

Per share measures	2021	2022	2023	2024	2025E	2026E	2027E
Number of shares (million)	14.66	14.66	14.66	14.66	14.66	14.66	14.66
Number of shares (diluted, million)	15.16	15.16	14.66	14.66	14.66	14.66	14.66
EPS	0.63	0.35	0.38	0.76	0.45	0.77	0.98
Operating cash flow per share	0.49	–0.02	0.73	1.30	0.53	0.80	0.95
Free cash flow per share	0.39	–0.13	1.44	1.15	0.42	0.44	0.64
Book value per share	5.02	4.96	4.97	5.62	5.58	6.05	6.52
Dividend per share	0.35	0.20	0.23	0.50	0.30	0.51	0.65
Dividend payout ratio, %	55.4%	57.0%	61.3%	66.0%	66.0%	66.0%	66.0%
Dividend yield, %	1.2%	1.2%	1.7%	3.3%	2.8%	4.7%	6.0%
FCF yield, %	1.3%	–0.8%	10.5%	7.5%	3.9%	4.1%	5.9%

Efficiency measures	2021	2022	2023	2024	2025E	2026E	2027E
ROE	14.0%	7.0%	7.6%	14.3%	8.1%	13.3%	15.6%
ROCE	15.1%	7.7%	10.6%	17.0%	10.9%	17.3%	18.9%

Financial ratios	2021	2022	2023	2024	2025E	2026E	2027E
Inventories as % of sales	24.8%	25.2%	22.7%	21.2%	23.0%	23.0%	23.0%
Receivables as % of sales	34.8%	36.2%	33.8%	31.1%	33.0%	33.0%	33.0%
Non–int. bearing liabilities as % of sales	17.1%	14.2%	13.4%	15.1%	15.1%	15.1%	15.1%
NWC/sales, %	41.3%	45.6%	41.8%	35.9%	39.5%	39.6%	39.7%
Operative CAPEX/Sales, %	1.5%	1.7%	1.9%	2.1%	1.7%	4.8%	3.8%
CAPEX/sales (incl. acquisitions), %	1.5%	1.7%	13.9%	2.1%	1.7%	4.8%	3.8%
FCFF/EBITDA	0.4	–0.2	1.9	1.0	0.6	0.3	0.4
Net Debt/EBITDA, book–weighted	–2.0	–2.3	–1.1	–1.7	–2.3	–1.5	–1.4
Debt/equity, market–weighted	0.0	0.0	0.0		0.0	0.0	
Equity ratio, book–weighted	0.8	0.8	0.8	0.8	0.8	0.8	0.8
Gearing, %	–37.6%	–28.3%	–17.7%	–34.2%	–33.1%	–32.8%	–32.4%

COMPANY DESCRIPTION: Detection Technology is a global provider of off-the-shelf and customized X-ray imaging solutions for medical, security and industrial applications. DT's product portfolio ranges from photodiodes to complete detector systems with ASICs, electronics, mechanics and software. The company was established in 1991 and it listed on Nasdaq First North Finland in 2015. The company is headquartered in Finland and has volume production in Beijing, China. Detection Technology has ~450 employees in Finland, China, France and USA, serving 370 active customers in over 40 countries.

INVESTMENT CASE: Demand for Detection Technology's detector solutions is increasing due to expansion of healthcare to a wider share of population in the emerging economies, aging population, growth in travelling and freight transport, urbanization, increased security concerns and increasing need for X-ray imaging applications in industrial inspection. We see investment case attractive due to strong market drivers, especially in China, as well as DT's compelling strategy and execution capabilities, which should enable DT to grow faster than the market and maintain above target level margins. Supported by the underlying megatrends and market expansion in TFT-flat panel markets, DT has lots of long-term potential in our view. Low valuation compared to historical multiples and peers provides a decent yield also on a short-term in our view.

OWNERSHIP STRUCTURE	SHARES	EURm	%
Ahlstrom Capital Bv	5 280 167	57.026	36.0 %
OP-Finland Fund	617 376	6.668	4.2 %
Varma Mutual Pension Insurance Company	515 000	5.562	3.5 %
Sijoitusrahasto Aktia Capital	463 654	5.007	3.2 %
Iimarinen Mutual Pension Insurance Company	435 737	4.706	3.0 %
Martola Hannu Veikko	431 690	4.662	2.9 %
Veritas Pension Insurance Company Ltd.	389 387	4.205	2.7 %
Evli Finnish Small Cap Fund	352 000	3.802	2.4 %
OP-Finland Small Firms Fund	330 019	3.564	2.3 %
Säästöpankki Kotimaa	260 000	2.808	1.8 %
Ten largest	9 075 030	98.010	61.9 %
Residual	5 580 900	60.274	38.1 %
Total	14 655 930	158.284	100%

EARNINGS CALENDAR

February 05, 2026	FY 2025 Results
April 23, 2026	Q1 report
August 06, 2026	Q2 report
October 29, 2026	Q3 report

OTHER EVENTS

COMPANY MISCELLANEOUS

CEO: Hannu Martola	Elektroniikkatie 10, 90590 Oulu
CFO: Matti Nylander	Tel: +358 20 766 9700
IR: Johanna Tarkiainen	

DEFINITIONS

P/E $\frac{\text{Price per share}}{\text{Earnings per share}}$	EPS $\frac{\text{Profit before extraord. items and taxes} - \text{income taxes} + \text{minority interest}}{\text{Number of shares}}$
P/BV $\frac{\text{Price per share}}{\text{Shareholder's equity} + \text{taxed provisions per share}}$	DPS Dividend for the financial period per share
Market cap Price per share * Number of shares	OCF (Operating cash flow) EBITDA – Net financial items – Taxes – Increase in working capital – Cash NRIs ± Other adjustments
EV (Enterprise value) Market cap + net debt + minority interest at market value – share of associated companies at market value	FCF (Free cash flow) Operating cash flow – Operative CAPEX – acquisitions + divestments
EV/Sales $\frac{\text{Enterprise value}}{\text{Sales}}$	FCF yield, % $\frac{\text{Free cash flow}}{\text{Market cap}}$
EV/EBITDA $\frac{\text{Enterprise value}}{\text{Earnings before interest, tax, depreciation and amortization}}$	Operative CAPEX / Sales $\frac{\text{Capital expenditure} - \text{divestments} - \text{acquisitions}}{\text{Sales}}$
EV/EBIT $\frac{\text{Enterprise value}}{\text{Operating profit}}$	Net working capital Current assets – current liabilities
Net debt Interest bearing debt – financial assets	Capital employed / Share $\frac{\text{Total assets} - \text{non-interest bearing debt}}{\text{Number of shares}}$
Total assets Balance sheet total	Gearing $\frac{\text{Net debt}}{\text{Equity}}$
Div yield, % $\frac{\text{Dividend per share}}{\text{Price per share}}$	Debt/Equity, % $\frac{\text{Interest bearing debt}}{\text{Shareholders' equity} + \text{minority interest} + \text{taxed provisions}}$
Payout ratio, % $\frac{\text{Total dividends}}{\text{Earnings before extraordinary items and taxes} - \text{income taxes} + \text{minority interest}}$	Equity ratio, % $\frac{\text{Shareholders' equity} + \text{minority interest} + \text{taxed provisions}}{\text{Total assets} - \text{interest-free loans}}$
ROCE, % $\frac{\text{Profit before extraordinary items} + \text{interest expenses} + \text{other financial costs}}{\text{Balance sheet total} - \text{non-interest bearing debt (average)}}$	CAGR, % Cumulative annual growth rate = Average growth rate per year
ROE, % $\frac{\text{Profit before extraordinary items and taxes} - \text{income taxes}}{\text{Shareholders' equity} + \text{minority interest} + \text{taxed provisions (average)}}$	

Important Disclosures

Evli Research Partners Plc ("ERP") uses 12-month target prices. Target prices are defined by utilizing analytical techniques based on financial theory including (but not limited to) discounted cash flow analysis and comparative valuation. The selection of valuation methods depends on different circumstances. Target prices may be altered on the basis of new information coming to light in the underlying company or changes in interest rates, changes in foreign exchange rates, other securities prices or market indices or outlook for the aforementioned factors or other factors that may change the conditions of financial markets. The valuation assumptions used are sensitive to changes and can significantly affect fair values. A change of a single percentage point in any used assumption could affect fair values by more than +/-20%. Recommendations and changes by analysts are available at [Analysts' recommendations and ratings revisions](#).

Investment recommendations are defined as follows:

Target price compared to share price

< -10 %

-10 - 0 %

0 - (+10) %

> 10 %

Recommendation

SELL


RECUDE

ACCUMULATE

BUY

ERP may temporarily suspend the rating and, if applicable, the target price to comply with regulations and/or firm policies, in which case a NOT RATED classification is used.

ERP's investment recommendation of the analyzed company is updated at least 2 times per year.



The graph above shows the distribution of ERP's recommendations of companies under coverage on the 16th of May, 2025. If recommendation is not given, it is not mentioned here.

Name(s) of the analyst(s): Joonas Ilvonen

This research report has been prepared by Evli Research Partners Plc ("ERP" or "Evli Research"). ERP is a subsidiary of Evli Plc. Production of the investment recommendation has been concluded on [19.11.2025, 9:05]. This report has been published on [19.11.2025, 9:25].

None of the analysts contributing to this report, persons under their guardianship or corporations under their control have a position in the shares of the company or related securities.

The date and time for any price of financial instruments mentioned in the recommendation refer to the previous trading day's closing price(s) unless otherwise stated in the report.

Each analyst responsible for the content of this report assures that the expressed views accurately reflect the personal views of each analyst on the covered companies and securities. Each analyst assures that (s)he has not been, nor are or will be, receiving direct or indirect compensation related to the specific recommendations or views contained in this report.

Companies in the Evli Group, affiliates or staff of companies in the Evli Group, may perform services for, solicit business from, hold long or short positions in, or otherwise be interested in the investments (including derivatives) of any company mentioned in the publication or report.

According to ERP's best knowledge, the issuer(s) of the securities does/(do) not hold in excess of 5% of the total issued share capital of the issuer(s).

Neither ERP nor any company within the Evli Group have managed or co-managed a public offering of the company's securities during the last 12 months prior to, received compensation for investment banking services from the company during the last 12 months prior to the publication of the research report.

ERP has signed an agreement with the issuer of the financial instruments mentioned in the recommendation, which includes production of research reports. This assignment has a limited economic and financial impact on ERP and/or Evli. Under the assignment ERP performs services including, but not limited to, arranging investor meetings or –events, investor relations communication advisory and production of research material.

ERP or another company within the Evli Group does not have an agreement with the company to perform market making or liquidity providing services.

For the prevention and avoidance of conflicts of interests with respect to this report, there is an information barrier (Chinese wall) between Investment Research and Corporate Finance units concerning unpublished investment banking services to the company. The remuneration of the analyst(s) is not tied directly or indirectly to investment banking transactions or other services performed by Evli Plc or any company within Evli Group.

This report has not been disclosed to the company prior to its dissemination.

This report is provided and intended for informational purposes only and may not be used or considered under any circumstances as an offer to sell or buy any securities or as advice to trade any securities.

This report is based on sources ERP considers to be correct and reliable. The sources include information providers FactSet and Bloomberg, stock-exchange releases from the companies and other company news, and publicly available online sources. However, ERP does not guarantee the materialization, correctness, accuracy or completeness of the information, opinions, estimates or forecasts expressed or implied in the report. In addition, circumstantial changes may have an influence on opinions and estimates presented in this report. The opinions and estimates presented are valid at the moment of their publication and they can be changed without a separate announcement. Neither ERP nor any company within the Evli Group are responsible for amending, correcting or updating any information, opinions or estimates contained in this report. Neither ERP nor any company within the Evli Group will compensate any direct or consequential loss caused by or derived from the use of the information represented in this publication.

All information published in this report is for the original recipient's private and internal use only. ERP reserves all rights to the report. No part of this publication may be reproduced or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, or stored in any retrieval system of any nature, without the written permission of ERP.

This report or its copy may not be published or distributed in Australia, Canada, Hong Kong, Japan, New Zealand, Singapore or South Africa. The publication or distribution of this report in certain other jurisdictions may also be restricted by law. Persons into whose possession this report comes are required to inform themselves about and to observe any such restrictions.

Evli Plc is not registered as a broker-dealer with the U. S. Securities and Exchange Commission ("SEC"), and it and its analysts are not subject to SEC rules on securities analysts' certification as to the currency of their views reflected in the research report. Evli Bank is not a member of the Financial Industry Regulatory Authority ("FINRA"). It and its securities analysts are not subject to FINRA's rules on Communications with the Public and Research Analysts and Research Reports and the attendant requirements for fairness, balance and disclosure of potential conflicts of interest. This research report is only being offered in U.S. by Auerbach Grayson & Company, LLC (Auerbach Grayson) to Major U.S. Institutional Investors and is not available to, and should not be used by, any U.S. person or entity that is not a Major U.S. Institutional Investor. Auerbach Grayson is a broker-dealer registered with the U.S. Securities and Exchange Commission and is a member of the FINRA. U.S. entities seeking more information about any of the issuers or securities discussed in this report should contact Auerbach Grayson. The securities of non-U.S. issuers may not be registered with or subject to SEC reporting and other requirements.

ERP is not a supervised entity but its parent company Evli Plc is supervised by the Finnish Financial Supervision Authority.

Contact information**SALES, TRADING AND RESEARCH****Equity Sales & Trading**

Joachim Dannberg (head)	+358 9 4766 9123
Aleksi Jalava	+358 9 4766 9123
Pasi Väisänen	+358 9 4766 9123

Evli Investment Solutions

Johannes Asuja	+358 9 4766 9205
----------------	------------------

Equity Research

Jerker Salokivi (head)	+358 9 4766 9149
Joonas Ilvonen	+358 44 430 9071
Atte Jortikka	+358 40 054 3725
Atte Pitkälampi	+358 44 047 6597

EVLI

EVLI PLC
Aleksanterinkatu 19 A
P.O. Box 1081
FIN-00101 Helsinki, FINLAND
Phone +358 9 476 690
Internet www.evli.com
E-mail firstname.lastname@evli.com

**EVLI PLC,
STOCKHOLMSFILIAL**
Regeringsgatan 67 P.O. Box 16354
SE-103 26 Stockholm
Sverige
stockholm@evli.com
Tel +46 (0)8 407 8000